Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain

Molecular Pharmacology

Volumn 70, Issue 6, 2006, Pages 1876-1884

  Faraco, Giuseppe ^a   Pancani, Tristano ^a   Formentini, Laura ^a   Mascagni, Paolo ^b   Fossati, Gianluca ^b   Leoni, Flavio ^b   Moroni, Flavio ^a   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PROTEIN BCL 2; PROTEIN KINASE B; SUBEROYLANILIDE HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; GENE CONTROL; GENE EXPRESSION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STROKE; STUDENT T TEST;

ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN ISCHEMIA; ENZYME INHIBITORS; GENE EXPRESSION; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL;

EID: 33751120697     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.027912     Document Type: Article

References (47)

1. Antonawich FJ, Federoff HJ, and Davis JN (1999) BCL-2 transduction, using a herpes simplex virus amplicon, protects hippocampal neurons from transient global ischemia. Exp Neurol 156:130-137.
2. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, and Richon VM (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170.
3. Calvani M and Arrigoni-Martelli E (1999) Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 21:1-6.
4. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, et al. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164:10-21.
5. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, and Li H (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 98:9808-9813.
6. Chen J, Graham SH, Chan PH, Lan J, Zhou RL, and Simon RP (1995) Bcl-2 is expressed in neurons that survive focal ischemia in the rat. NeuroReport 6:394-398.
7. Chen J, Graham SH, Nakayama M, Zhu RL, Jin K, Stetler RA, and Simon RP (1997) Apoptosis repressor genes Bcl-2 and Bcl-x-Long are expressed in the rat brain following global ischemia. J Cereb Blood Flow Metab 17:2-10.
8. Chen J, Graham SH, Zhu RL, and Simon RP (1996) Stress proteins and tolerance to focal cerebral ischemia. J Cereb Blood Flow Metab 16:566-577.
9. Cipriani G, Rapizzi E, Vannacci A, Rizzuto R, Moroni F, and Chiarugi A (2005) Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. J Biol Chem 280:17227-17234.
10. Corcoran LJ, Mitchison TJ, and Liu Q (2004) A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol 14:488-492.
11. Dirnagl U, Iadecola C, and Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391-397.
12. Dokmanovic M and Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293-304.
13. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23:9418-9427.
14. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280:556-563.
15. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo CF, Nervi C, Pelicci PG, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO (Eur Mol Biol Organ) J 20:6969-6978.
16. Hahnen E, Eyupoglu IY, Brichta L, Haastert K, Trankle C, Siebzehnrubl FA, Riessland M, Holker I, Claus P, Romstock J, et al. (2006) In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 98:193-202.
17. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 100:2041-2046.
18. Iadecola C and Alexander M (2001) Cerebral ischemia and inflammation. Curr Opin Neurol 14:89-94.
19. Jenuwein T and Allis CD (2001) Translating the histone code. Science (Wash DC) 293:1074-1080.
20. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299.
21. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, and Wu CW (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275:20436-20443.
22. Kouzarides T (2000) Acetylation: a Regulatory Modification to Rival Phosphorylation? EMBO (Eur Mol Biol Organ) J 19:1176-1179.
23. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99:2995-3000.
24. Letai A (2005) Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Investig 115:2648-2655.
25. Lo EH, Dalkara T, and Moskowitz MA (2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415.
26. Luo J, Su F, Chen D, Shiloh A, and Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature (Lond) 408:377-381.
27. Marks PA, Miller T, and Richon VM (2003) Histone deacetylases. Curr Opin Pharmacol 3:344-351.
28. Marks PA, Richon VM, Miller T, and Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137-168.
29. Marks PA, Richon VM, and Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216.
30. Martinou JC, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowski H, Missotten M, Albertini P, Talabot D, Catsicas S, Pietra C, et al. (1994) Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 13:1017-1030.
31. Minucci S and Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51.
32. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. (2005) An inhibitor of bcl-2 family proteins induces regression of solid tumours. Nature (Lond) 435:677-681.
33. Papadopoulos MC, Giffard RG, and Bell BA (2000) An introduction to the changes in gene expression that occur after cerebral ischaemia. Br J Neurosurg 14:305-312.
34. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, and Beal MF (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22:40-49.
35. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, and Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741.
36. Read SJ, Parsons AA, Harrison DC, Philpott K, Kabnick K, O' Brien S, Clark S, Brawner M, Bates S, Gloger I, et al. (2001) Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. J Cereb Blood Flow Metab 21:755-778.
37. Ren M, Leng Y, Jeong M, Leeds PR, and Chuang DM (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89:1358-1367.
38. Richon VM, Zhou X, Rifkind RA, and Marks PA (2001) Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 27:260-264.
39. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, and Ratan RR (2003) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 100:4281-4286.
40. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH Jr, et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93:1087-1098.
41. Saha RN and Pahan K (2006) HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 13:539-550.
42. Sharp FR, Massa SM, and Swanson RA (1999) Heat-shock protein protection. Trends Neurosci 22:97-99.
43. Stenzel-Poore MP, Stevens SL, and Simon RP (2004) Genomics of preconditioning. Stroke 35:2683-2686.
44. Swanson RA and Sharp FR (1994) Infarct measurement methodology. J Cereb Blood Flow Metab 14:697-698.
45. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, and Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678.
46. Weinstein PR, Hong S, and Sharp FR (2004) Molecular identification of the ischemic penumbra. Stroke 35:2666-2670.
47. Yano S, Morioka M, Fukunaga K, Kawano T, Hara T, Kai Y, Hamada J, Miyamoto E, and Ushio Y (2001) Activation of Akt/protein kinase B contributes to induction of ischemic tolerance in the CA1 subfield of gerbil hippocampus. J Cereb Blood Flow Metab 21:351-360.